Brought to you by 
Pfizer gets preclinical-stage cancer compounds from iTeos; IDO1 inhibitor returned
02 Feb 2023
Executive Summary
After recently scrapping a potential bid for AstraZeneca and its strong cancer pipeline, Pfizer Inc. licensed exclusive rights to iTeos Therapeutics SA’s preclinical oncology compounds aimed at indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO2).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer gets preclinical-stage cancer compounds from iTeos; IDO1 inhibitor returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice